Mark Enyedy
Director/Board Member chez ERGOMED
Fortune : 190 401 $ au 31/03/2024
Profil
Mark Joseph Enyedy is an Independent Director at BioMarin Pharmaceutical, Inc., a Director at Biotechnology Innovation Organization, and a Director at American Cancer Society New England Division, Inc. He is also an Independent Non-Executive Director at Ergomed Plc.
Previously, he was the President, Chief Executive Officer & Director at ImmunoGen, Inc., the Chief Executive Officer & Director at Proteostasis Therapeutics, Inc., and an Independent Director at Keryx Biopharmaceuticals, Inc. He was also an Independent Director at Akebia Therapeutics, Inc., an Independent Director at Fate Therapeutics, Inc., and an Independent Director at LogicBio Therapeutics, Inc. Additionally, he served as the SVP, President-Transplant & Multiple Sclerosis at Genzyme Corp.
and the Executive VP & Head-Corporate Development at Shire Plc.
He started his career as an Associate at Palmer & Dodge LLP.
Enyedy received his undergraduate degree from Northeastern University and his graduate degree from Harvard Law School.
He currently holds positions at BioMarin Pharmaceutical, Inc., Biotechnology Innovation Organization, American Cancer Society New England Division, Inc., and Ergomed Plc.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 27/12/2023 | 2 180 ( 0,00% ) | 190 401 $ | 31/03/2024 |
Postes actifs de Mark Enyedy
| Sociétés | Poste | Début |
|---|---|---|
| ERGOMED | Director/Board Member | 10/06/2021 |
| BIOMARIN PHARMACEUTICAL INC. | Director/Board Member | 27/12/2023 |
| American Cancer Society New England Division, Inc. | Director/Board Member | - |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Director/Board Member | - |
Anciens postes connus de Mark Enyedy
| Sociétés | Poste | Fin |
|---|---|---|
| IMMUNOGEN, INC. | Chief Executive Officer | 12/02/2024 |
| LOGICBIO THERAPEUTICS, INC. | Director/Board Member | 16/11/2022 |
| AKEBIA THERAPEUTICS, INC. | Director/Board Member | 02/06/2021 |
| KERYX BIOPHARMACEUTICALS | Director/Board Member | 12/12/2018 |
| FATE THERAPEUTICS, INC. | Director/Board Member | 02/05/2018 |
Formation de Mark Enyedy
| Northeastern University | Undergraduate Degree |
| Harvard Law School | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| IMMUNOGEN, INC. | Health Technology |
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| AKEBIA THERAPEUTICS, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| ERGOMED | Commercial Services |
| Entreprise privées | 8 |
|---|---|
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
| Palmer & Dodge LLP | Commercial Services |
Proteostasis Therapeutics, Inc.
 Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA. | Health Technology |
| American Cancer Society New England Division, Inc. | |
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
